Informa’s stock rose as much as 7.5% yesterday, reaching its highest level since March 2020, after the company confirmed the sale of its Pharma Intelligence business for £1.9bn and the commencement of its share buy-back programme, in line with the GAP II strategy laid out at its CMD in December. The company also raised its FY21e guidance. A shareholder’s delight…
